| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P356 | DOI | 10.1007/S40261-014-0222-1 |
| P698 | PubMed publication ID | 25096848 |
| P2093 | author name string | Qing Zhang | |
| Xiao-Mao Guo | |||
| Shen Fu | |||
| Wei-Xiang Qi | |||
| P2860 | cites work | Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 |
| Meta-analysis in clinical trials | Q27860779 | ||
| Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 | ||
| Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature | Q29614233 | ||
| Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer | Q29614302 | ||
| Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma | Q29617568 | ||
| Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? | Q29619328 | ||
| Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study | Q29620647 | ||
| Improved survival with bevacizumab in advanced cervical cancer | Q33566222 | ||
| Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206 | Q33813718 | ||
| Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer | Q34022546 | ||
| A phase 3 trial of bevacizumab in ovarian cancer | Q34030022 | ||
| Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials | Q34554398 | ||
| Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial | Q34555503 | ||
| Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial | Q34586436 | ||
| Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial | Q34656044 | ||
| Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer | Q36024588 | ||
| Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. | Q36058291 | ||
| Bevacizumab added to neoadjuvant chemotherapy for breast cancer | Q36106083 | ||
| OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer | Q36822179 | ||
| Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials | Q37721064 | ||
| Cardiovascular toxicity of anti-angiogenic drugs | Q37960873 | ||
| AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer | Q38097423 | ||
| Congestive heart failure risk in patients with breast cancer treated with bevacizumab. | Q44082273 | ||
| RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer | Q44963911 | ||
| Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer | Q46502913 | ||
| Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma | Q46796397 | ||
| Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial | Q47815963 | ||
| Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. | Q53087417 | ||
| Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. | Q54534083 | ||
| Heterogeneity testing in meta-analysis of genome searches | Q81128804 | ||
| RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic br | Q85077949 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bevacizumab | Q413299 |
| meta-analysis | Q815382 | ||
| congestive heart failure | Q19000661 | ||
| P304 | page(s) | 681-690 | |
| P577 | publication date | 2014-10-01 | |
| P1433 | published in | Clinical Drug Investigation | Q15753215 |
| P1476 | title | Bevacizumab increases the risk of severe congestive heart failure in cancer patients: an up-to-date meta-analysis with a focus on different subgroups | |
| P478 | volume | 34 |
| Q39053477 | Biomarkers for monitoring chemotherapy-induced cardiotoxicity |
| Q30276456 | Cancer treatment-related cardiac toxicity: prevention, assessment and management |
| Q56991273 | Cardiotoxicity with vascular endothelial growth factor inhibitor therapy |
| Q38744149 | Cardiovascular adverse effects of targeted antiangiogenic drugs: mechanisms and management |
| Q57141680 | Contemporary Updates on Clinical Trials of Antiangiogenic Agents in the Treatment of Glioblastoma Multiforme |
| Q53225923 | Current opinion on bevacizumab on endometrial cancer treatment. |
| Q47346411 | Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients. |
| Q37042424 | Risk of venous and arterial thromboembolic events associated with anti-VEGF agents in advanced non-small-cell lung cancer: a meta-analysis and systematic review |
| Q33659820 | Sorafenib-Associated Heart Failure Complicated by Cardiogenic Shock after Treatment of Advanced Stage Hepatocellular Carcinoma: A Clinical Case Discussion |
| Q38367620 | The role for microRNAs in drug toxicity and in safety assessment |
Search more.